Metabolic syndrome prevalence is high in the U.S.
the ONA take:
Researchers have found a high prevalence of metabolic syndrome in the US population. Estimates are nearly 35% of all US adults and 50% of those 60 years and older in 2011-2012 have the condition.
Metabolic syndrome is a combination of health conditions, including obesity, high blood pressure, elevated blood sugar, and poor lipid profile that contribute to cardiovascular illness and death.
Researchers used National Health and Nutrition Examination Survey (NHANES) 2003-2012 data to evaluate trends in metabolic syndrome among adults age 20 years and older. Prevalence was higher in women compared with men.
When stratified by race/ethnicity, the highest prevalence was in Hispanics, followed by non-Hispanic whites and blacks. Overall prevalence increased from 32.9% in 2003-2004 to 34.7% in 2011-2012.
By age groups, prevalence of metabolic syndrome increased by age groups. Among people age 20 to 39 years, prevalence was 18.3%, and it increased to 46.7% among those 60 years or older. The researchers defined this as “a concerning observation given the aging US population.”
Greater awareness of the condition and its health consequences may be contributing to improved treatment of risk factors. Finally, recent NHANES data demonstrate that obesity rates are stabilizing, which may lead to stabilizing the prevalence of metabolic syndrome as well.
Researchers have found a high prevalence of metabolic syndrome in the US population.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|